Endocrinology Archives - Corcept Therapeutics

Prevalence of Hypercortisolism in Individuals With Resistant Hypertension and Cardiovascular Disease

July 31, 2026

Taub et al. • 2026 • ASPC

Prevalence of Endogenous Hypercortisolism in Individuals With Resistant Hypertension Stratified by Kidney Function: Results From the MOMENTUM Study

June 22, 2026

DeFronzo et al. • 2026 • Heart in Diabetes

Endogenous Hypercortisolism in Individuals With Resistant Hypertension and Difficult-to-Control Type 2 Diabetes: Results From Two Large, Prospective Studies

June 15, 2026

DeFronzo et al. • 2026 • ENDO

Characterization of Individuals With Resistant Hypertension and Post-Dexamethasone Suppression Test Cortisol <1.2, 1.2–1.8, and >1.8 μg/dL: Results From the MOMENTUM Study

June 15, 2026

Eilerman et al. • 2026 • ENDO

High Prevalence of Endogenous Hypercortisolism in Patients With Type 2 Diabetes and Resistant Hypertension: Results From the MOMENTUM Study

June 8, 2026

Umpierrez et al. • 2026 • ADA

Effects of Mifepristone in People With Difficult-to-Control T2D and Hypercortisolism on GLP-1 RAs

June 6, 2026

Sloan et al. • 2026 • ADA

Co-secretion of Cortisol and Aldosterone in Individuals With Resistant Hypertension: Results From the MOMENTUM Trial

April 24, 2026

Sloan et al. • 2026 • AACE

Relacorilant Treatment Improves Glycemic Control Among Individuals With Cushing Syndrome (Endogenous Hypercortisolism) and Hyperglycemia on Glucagon-Like Peptide-1 Receptor Agonists: Insights From a Phase 3 Study

April 24, 2026

Silverstein et al. • 2026 • AACE

Prevalence and Clinical Impact of Hypercortisolism in Patients With Resistant Hypertension: Primary Results From the MOMENTUM Study

March 28, 2026

Bhatt et al. • 2026 • ACC.26

Efficacy and Safety of Relacorilant for the Treatment of Patients With Cushing’s Syndrome (GRACE): A Multicentre, Phase 3, Double-Blind, Placebo-Controlled, Randomised-Withdrawal Study

February 20, 2026

Pivonello • 2026 • The Lancet Diabetes & Endocrinology